Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape

Journal of Virology

Volumn 79, Issue 3, 2005, Pages 1645-1654

  Leonard, Joshua N ^a   Schaffer, David V ^a  

^a University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RNA; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; EVOLUTION; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; INNATE IMMUNITY; MATHEMATICAL ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RNA INTERFERENCE; STOCHASTIC MODEL; VIRUS GENOME; VIRUS MUTANT; BIOLOGICAL MODEL; BIOLOGY; EVALUATION; GENE THERAPY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; METHODOLOGY; PHYSIOLOGY; STATISTICS; VIROLOGY; VIRUS REPLICATION;

COMPUTATIONAL BIOLOGY; DRUG DESIGN; GENE PRODUCTS, TAT; GENE THERAPY; HIV INFECTIONS; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; MODELS, BIOLOGICAL; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOCHASTIC PROCESSES; VIRUS REPLICATION;

EID: 13744250051     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.3.1645-1654.2005     Document Type: Article

References (72)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Anderson, J., A. Banerjea, and R. Akkina. 2003. Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 13:303-312.
3. + progenitor cell-derived macrophages. Mol. Ther. 8:62-71.
4. Berkhout, B. 2004. RNA interference as an antiviral approach: targeting HIV-1. Curr. Opin. Mol. Ther. 6:141-145.
5. Berkhout, B., and K. T. Jeang. 1989. trans activation of human immunodeficiency virus type 1 is sequence specific for both the single-stranded bulge and loop of the trans-acting-responsive hairpin: a quantitative analysis. J. Virol. 63:5501-5504.
6. Boden, D., O. Pusch, F. Lee, L. Tucker, and B. Ramratnam. 2003. Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77:11531-11535.
7. Das, A. T., T. R. Brummelkamp, E. M. Westerhout, M. Vink, M. Madiredjo, R. Bernards, and B. Berkhout. 2004. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78:2601-2605.
8. Davis, B. M., L. Humeau, and B. Dropulic. 2004. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol. Ther. 9:160-172.
9. Denli, A. M., and G. J. Hannon. 2003. RNAi: an ever-growing puzzle. Trends Biochem. Sci. 28:196-201.
10. Di Mascio, M., R. M. Ribeiro, M. Markowitz, D. D. Ho, and A. S. Perelson. 2004. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math. Biosci. 188:47-62.
11. Dingwall, C., I. Ernberg, M. J. Gait, S. M. Green, S. Heaphy, J. Karn, A. D. Lowe, M. Singh, and M. A. Skinner. 1990. HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J. 9:4145-4153.
12. Domingo, E. 2001. Quasispecies and RNA virus evolution: principles and consequences. Landes Bioscience, Georgetown, Tex.
13. Domingo, E., R. G. Webster, and J. J. Holland. 1999. Origin and evolution of viruses. Academic Press, San Diego, Calif.
14. Feng, S., and E. C. Holland. 1988. HIV-1 tat trans-activation requires the loop sequence within tar. Nature 334:165-167.
15. Fire, A., S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
16. Fleming, P. L., R. H. Byers, P. A. Sweeney, D. Daniels, J. M. Karon, and R. S. Janssen. 2000. HIV prevalence in the United States, 2000. Abstr. 9th Conf. Retroviruses Opportunistic Infect. 2000, abstr. 11.
17. Garter, D. A., G. Silvestri, and M. B. Feinberg. 2004. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect. Dis. 4:397-413.
18. Garcia, J. A., D. Harrich, E. Soultanakis, F. Wu, R. Mitsuyasu, and R. B. Gaynor. 1989. Human immunodeficiency virus type 1 LTR TATA and TAR region sequences required for transcriptional regulation. EMBO J. 8:765-778.
19. Ge, Q., M. T. McManus, T. Nguyen, C. H. Shen, P. A. Sharp, H. N. Eisen, and J. Chen. 2003. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. USA 100:2718-2723.
20. Gitlin, L., S. Karelsky, and R. Andino. 2002. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418:430-434,
21. + donors. J. Med. Virol. 70:183-186.
22. Gupta, S., R. A. Schoer, J. E. Egan, G. J. Hannon, and V. Mittal. 2004. Inducible, reversible, and stable RNA interference in mammalian cells. Proc. Natl. Acad. Sci. USA 101:1927-1932.
23. Hacein-Bey-Abina, S., A. Fischer, and M. Cavazzana-Calvo. 2002. Gene therapy of X-linked severe combined immunodeficiency. Int. J. Hematol. 76:295-298.
24. Hamada, M., T. Ohtsuka, R. Kawaida, M. Koizumi, K. Morita, H. Funikawa, T. Imanishi, M. Miyagishi, and K. Taira. 2002. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev. 12:301-309.
25. Hauber, J., and B. R. Cullen. 1988. Mutational analysis of the trans-activation-responsive region of the human immunodeficiency virus type I long terminal repeat. J. Virol. 62:673-679.
26. Holen, T., M. Amarzguioui, M. T. Wiiger, E. Babaie, and H. Prydz. 2002. Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. 30:1757-1766.
27. Holmes, E. C., and A. Moya. 2002. Is the quasispecies concept relevant to RNA viruses? J. Virol. 76:460-465.
28. + infected patients grouped according to CD4 count and viral load. Mol. Ther. 9:902-913.
29. Huthoff, H., and B. Berkhout. 2001. Mutations in the TAR hairpin affect the equilibrium between alternative conformations of the HIV-1 leader RNA. Nucleic Acids Res. 29:2594-2600.
30. Jacque, J. M., K. Triques, and M. Stevenson. 2002. Modulation of HIV-1 replication by RNA interference. Nature 418:435-438.
31. Jakobovits, A., D. H. Smith, E. B. Jakobovits, and D. J. Capon. 1988. A discrete element 3′ of human immunodeficiency virus 1 (HIV-1) and HIV-2 mRNA initiation sites mediates transcriptional activation by an HIV trans activator. Mol. Cell. Biol. 8:2555-2561.
32. Jenkins, G. M., M. Worobey, C. H. Woelk, and E. C. Holmes. 2001. Evidence for the non-quasispecies evolution of RNA viruses [corrected]. Mol. Biol. Evol. 18:987-994.
33. Jetzt, A. E., H. Yu, G. J. Klarmann, Y. Ron, B. D. Preston, and J. P. Dougherty. 2000. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J. Virol. 74:1234-1240.
34. Jordan, A., P. Defechereux, and E. Verdin. 2001. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 20:1726-1738.
35. Kijak, G. H., V. Simon, P. Balfe, J. Vanderhoeven, S. E. Pampuro, C. Zala, C. Ochoa, P. Cahn, M. Markowitz, and H. Salomon. 2002. Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J. Virol. 76:7000-7009.
36. Kim, D. H., M. Longo, Y. Han, P. Lundberg, E. Cantin, and J. J. Rossi. 2004. Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat. Biotechnol. 22:321-325.
37. Kimura, M. 1994. Population genetics, molecular evolution, and the neutral theory; selected papers. University of Chicago Press, Chicago.
38. Klaver, B., and B. Berkhout. 1994. Premature strand transfer by the HIV-1 reverse transcriptase during strong-stop DNA synthesis. Nucleic Acids Res. 22:137-144.
39. Layden, T. J., J. E. Layden, R. M. Ribeiro, and A. S. Perelson. 2003. Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. Clin. Liver Dis. 7:163-178.
40. Lee, N. S., and J. J. Rossi. 2004. Control of HIV-1 replication by RNA interference. Virus Res. 102:53-58.
41. Leirdal, M., and M. Sioud. 2002. Gene silencing in mammalian cells by pre-formed small RNA duplexes. Biochem. Biophys. Res. Commun. 295:744-748.
42. Li, M. J., G. Bauer, A. Michienzi, J. K. Yee, N. S. Lee, J. Kim, S. Li, D. Castanotto, J. Zaia, and J. J. Rossi. 2003. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol. Ther. 8:196-206.
43. Lu, X., Q. Yu, G. K. Binder, Z. Chen, T. Slepushkina, J. Rossi, and B. Dropulic. 2004. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J. Virol. 78:7079-7088.
44. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase, J. Virol. 69:5087-5094.
45. Michienzi, A., D. Castanotto, N. Lee, S. Li, J. A. Zaia, and J. J. Rossi. 2003. RNA-mediated inhibition of HIV in a gene therapy setting. Ann. N. Y. Acad. Sci. 1002:63-71.
46. Miller, V. M., H. Xia, G. L. Marrs, C. M. Gouvion, G. Lee, B. L. Davidson, and H. L. Paulson. 2003. Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. USA 100:7195-7200.
47. Muller, V., and S. Bonhoeffer. 2003. Mathematical approaches in the study of viral kinetics and drug resistance in HIV-1 infection. Curr. Drug Targets Infect. Disord. 3:329-344.
48. Ou, S. H., F. Wu, D. Harrich, L. F. Garcia-Martinez, and R. B. Gaynor. 1995. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol. 69:3584-3596.
49. Paddison, P. J., A. A. Caudy, and G. J. Hannon. 2002. Stable suppression of gene expression by RNAi in mammalian cells. Proc. Natl. Acad. Sci. USA 99:1443-1448.
50. Parrish, S., J. Fleenor, S. Xu, C. Mello, and A. Fire. 2000. Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol. Cell 6:1077-1087.
51. Radhakrishnan, S. K., T. J. Layden, and A. L. Gartel. 2004. RNA interference as a new strategy against viral hepatitis. Virology 323:173-181.
52. Rambaut, A., D. Posada, K. A. Crandall, and E. C. Holmes. 2004. The causes and consequences of HIV evolution. Nat. Rev. Genet. 5:52-61.
53. Reddy, B., and J. Yin, 1999. Quantitative intracellular kinetics of HIV type 1. AIDS Res. Hum. Retrovir. 15:273-283.
54. Reynolds, A., D. Leake, Q. Boese, S. Scaringe, W. S. Marshall, and A. Khvorova. 2004. Rational siRNA design for RNA interference. Nat. Biotechnol. 22:326-330.
55. Scacheri, P. C., O. Rozenblatt-Rosen, N. J. Caplen, T. G. Wolfsberg, L. Umayam, J. C. Lee, C. M. Hughes, K. S. Shanmugam, A. Bhattacharjee, M. Meyerson, and F. S. Collins. 2004. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. USA 101:1892-1897.
56. Scherr, M., K. Battmer, A. Ganser, and M. Eder. 2003. Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2:251-257.
57. Schroder, A. R., P. Shinn, H. Chen, C. Berry, J. R. Ecker, and F. Bushman. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110:521-529.
58. Selby, M. J., E. S. Bain, P. A. Luciw, and B. M. Peterlin. 1989. Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. Genes Dev. 3:547-558.
59. Simm, M., W. Chao, O. Pekarskaya, P. Sova, P. Gupta, R. Balachandran, and D. J. Volsky. 1996. Genetic variability and function of the long terminal repeat from syncytium-inducing and non-syncytium-inducing human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 12:801-809.
60. Sledz, C. A., M. Holko, M. J. de Veer, R. H. Silverman, and B. R. Williams. 2003. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5:834-839.
61. ter Hofstede, H. J., D. M. Burger, and P. P. Koopmans. 2003. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity. Neth. J. Med. 61:393-403.
62. Verhoef, K., M. Koper, and B. Berkhout. 1997. Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication. Virology 237:228-236.
63. Vigoureux, C., S. Gharakhanian, Y. Salhi, T. H. Nguyen, N. Adda, W. Rozenbaum, and J. Capeau. 1999. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab. 25:383-392.
64. Weinberger, L. S., D. V. Schaffer, and A. P. Arkin. 2003. Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J. Virol. 77:10028-10036.
65. World Health Organization. 2004. AIDS epidemic update: December 2003. [Online.] http://www.who.int/hiv/pub/epidemiology/epi2003/en/.
66. Wiethoff, C. M., and C. R. Middaugh. 2003. Barriers to nonviral gene delivery. J. Pharm. Sci. 92:203-217.
67. Wiznerowicz, M., and D. Trono. 2003. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77:8957-8961.
68. Wodarz, D., and M. A. Nowak. 2002. Mathematical models of HIV pathogenesis and treatment. Bioessays 24:1178-1187.
69. Wu, F., J. Garcia, D. Sigman, and R. Gaynor. 1991. tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes Dev. 5:2128-2140.
70. Yam, P. Y., J. Wu, M. C. Jensen, J. A. Zaia, and J. K. Yee. 2004. Abstr. Am. Soc. Gene Ther. 7th Annu. Meet., abstr. 369, p. 71.
71. Yoshinari, K., M. Miyagishi, and K. Taira. 2004. Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res. 32:691-699.
72. Zhu, Y., T. Pe'ery, J. Peng, Y. Ramanathan, N. Marshall, T. Marshall, B. Amendt, M. B. Mathews, and D. H. Price. 1997. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev. 11:2622-2632.